Boosting blood flow and insulin to enhance Alzheimer's treatment
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This study tests whether adding a treatment that improves blood vessel and insulin function can make the standard Alzheimer's medication work better for people with mild Alzheimer's or mild cognitive impairment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild cognitive impairment due to Alzheimer's or mild Alzheimer's disease.
- You have had a positive test for amyloid plaques (via PET scan or spinal fluid) or your doctor confirms this.
- You have been on a stable dose of an anti-amyloid drug (like Leqembi or Kisunla) for at least 8 weeks.
- You are fluent in English and have a study partner (like a family member or friend) who can spend about 10 hours per week with you.
- You do not have diabetes or take insulin or other diabetes medications.
- You have not had a stroke, seizure, or major head injury in the past two years.
- You do not have a history of immune diseases (like lupus or rheumatoid arthritis) or take immunosuppressants.
- You are not taking blood thinners and do not have bleeding disorders.
- You are able to have an MRI (no metal implants or pacemaker, no severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special form of a dietary fat called tricaprilin can help people with mild-to-moderate Alzheimer's disease. It may provide an alternative or add-on to current treatments to help with memory and thinking.
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This study tests if a combination of insulin and semaglutide (a diabetes drug) can improve memory and thinking in people with mild cognitive impairment (MCI) who also have metabolic syndrome (a cluster of health issues like large waist, high blood sugar, and high blood pressure). It aims to see if treating blood sugar problems helps protect the brain.
This trial tests a drug called masitinib to see if it can help people with mild Alzheimer's disease. You'd get either the drug or a placebo, and doctors will check if your daily living skills and memory slow their decline.
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.